AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17886195 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (education group)
Number of subjects: 184
Study 15295692 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic susceptibility score (PSS) weighted by inferred potency
Number of subjects: 0
Study 15295692 — intervention group
Group type: EXPERIMENTAL
Intervention: Entry VL
Number of subjects: 0
Study 11351770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate
Number of subjects: 0
Study 11351770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9827282 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus ethambutol
Number of subjects: 59
Study 9827282 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin plus ethambutol
Number of subjects: 59
Study 7603052 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based AIDS prevention program (10-lesson classroom program in seventh grade with a 5-lesson booster in eighth grade)
Number of subjects: 312
Study 7603052 — intervention group
Group type: COMPARATOR
Intervention: Basic AIDS education (current practice in their districts)
Number of subjects: 312
Study 7603052 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based AIDS prevention program
Number of subjects: 312
Study 2104735 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ergotamine tartrate (1 puff, 0.36 mg)
Number of subjects: 8
Study 2104735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 517990 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-releasing IUDs
Number of subjects: 0
Study 30266044 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimony regarding one piece of evidence
Number of subjects: 0
Study 30266044 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimony regarding two pieces of independent evidence
Number of subjects: 0
Study 30266044 — intervention group
Group type: EXPERIMENTAL
Intervention: Testimony regarding two pieces of interdependent evidence
Number of subjects: 0
Study 28603868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative ultrasound-guided infraclavicular brachial plexus block
Number of subjects: 52
Study 28603868 — intervention group
Group type: COMPARATOR
Intervention: Postoperative block with 0.5 ml.kg‐1 ropivacaine 0.75%
Number of subjects: 52
Study 26014587 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal donepezil patch 87.5 mg/25 cm(2) every 72 h
Number of subjects: 0
Study 26014587 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal donepezil patch 175 mg/50 cm(2) every 72 h
Number of subjects: 0
Study 23471752 — intervention group
Group type: EXPERIMENTAL
Intervention: New assessment form (experimental group)
Number of subjects: 8075
Study 23471752 — intervention group
Group type: COMPARATOR
Intervention: Existing assessment form (control group)
Number of subjects: 8075
Study 21716277 — intervention group
Group type: EXPERIMENTAL
Intervention: LBM415 at 1,000 mg b.i.d.
Number of subjects: 0
Study 21716277 — intervention group
Group type: EXPERIMENTAL
Intervention: LBM415 at 1,000 mg t.i.d.
Number of subjects: 0
Study 21716277 — intervention group
Group type: EXPERIMENTAL
Intervention: LBM415 at low doses (not specified)
Number of subjects: 0
Study 21716277 — intervention group
Group type: EXPERIMENTAL
Intervention: LBM415 at 1,000 mg single dose
Number of subjects: 0
Study 19330359 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Neurotoxicity Questionnaire (PNQ)
Number of subjects: 300
Study 19330359 — intervention group
Group type: COMPARATOR
Intervention: Physician assessments (National Cancer Institute Common Toxicity Criteria)
Number of subjects: 300
Study 16436850 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic
Number of subjects: 14
Study 16436850 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 14
Study 16436850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 14
Study 15296889 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 1.5 g as a bolus, followed by a constant infusion of 200 mg/h until 1.5 g
Number of subjects: 46
Study 15296889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 46
Study 11767232 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 148
Study 11767232 — intervention group
Group type: COMPARATOR
Intervention: Human regular insulin (HR)
Number of subjects: 148
Study 9237494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg)
Number of subjects: 8
Study 9237494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8001725 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt (0.2 M and 0.4 M)
Number of subjects: 0
Study 8001725 — intervention group
Group type: EXPERIMENTAL
Intervention: Salted formula (0.15 M)
Number of subjects: 0
Study 8001725 — intervention group
Group type: COMPARATOR
Intervention: Unsalted formula
Number of subjects: 0
Study 3053601 — intervention group
Group type: EXPERIMENTAL
Intervention: Theolair‐SR
Number of subjects: 23
Study 3053601 — intervention group
Group type: COMPARATOR
Intervention: Theo‐Dur
Number of subjects: 23
Study 31916788 — intervention group
Group type: EXPERIMENTAL
Intervention: WE PLAY program (4-week online preschool teacher training)
Number of subjects: 6
Study 31916788 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 6
Study 31476615 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive nonverbal behaviors directed by teachers toward one group
Number of subjects: 96
Study 31476615 — intervention group
Group type: COMPARATOR
Intervention: Negative nonverbal behaviors directed by teachers toward another group
Number of subjects: 96
Study 28303632 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 4303
Study 28303632 — intervention group
Group type: COMPARATOR
Intervention: UFH monotherapy
Number of subjects: 4303
Study 25348274 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary revascularization
Number of subjects: 313
Study 25348274 — intervention group
Group type: COMPARATOR
Intervention: Medical management in patients with impaired renal function
Number of subjects: 313
Study 23772918 — intervention group
Group type: EXPERIMENTAL
Intervention: White participants in a condition with Black confederates being profiled (racial profiling condition)
Number of subjects: 0
Study 23772918 — intervention group
Group type: COMPARATOR
Intervention: White participants in a White-profiling condition
Number of subjects: 0
Study 23772918 — intervention group
Group type: COMPARATOR
Intervention: White participants in a no-profiling control condition
Number of subjects: 0
Study 23772918 — intervention group
Group type: EXPERIMENTAL
Intervention: Black participants across all three conditions (racial profiling, White-profiling, no-profiling)
Number of subjects: 0
Study 21447471 — intervention group
Group type: EXPERIMENTAL
Intervention: Video iPods (educational technology intervention)
Number of subjects: 21
Study 21447471 — intervention group
Group type: COMPARATOR
Intervention: Control group (no technological intervention)
Number of subjects: 21
Study 19786240 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel
Number of subjects: 50
Study 19786240 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and placebo
Number of subjects: 50
Study 16684823 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (425 mg/d) for 2 years
Number of subjects: 38
Study 16684823 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 38
Study 15277255 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 i.v. followed by paclitaxel 150 mg/m2 i.v. over 24 h plus filgrastim 5 microg/kg on days 3-12 (arm 2)
Number of subjects: 317
Study 15277255 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m2 i.v. followed by cisplatin 50 mg/m2 i.v. (arm 1)
Number of subjects: 317
Study 11351769 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol via Aerolizer inhaler (12 micrograms twice daily)
Number of subjects: 200
Study 11351769 — intervention group
Group type: COMPARATOR
Intervention: Formoterol via Turbuhaler inhaler (12 micrograms twice daily)
Number of subjects: 200
Study 9236262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone (200 mg t.i.d.)
Number of subjects: 198
Study 9236262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 8237098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg
Number of subjects: 16
Study 8237098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg
Number of subjects: 16
Study 8237098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 20 mg
Number of subjects: 16
Study 3092363 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three interventions
Number of subjects: 0
Study 3092363 — intervention group
Group type: EXPERIMENTAL
Intervention: Triaging patients into various combinations of health education treatments
Number of subjects: 0
Study 3092363 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational history as a triaging variable
Number of subjects: 0
Study 3092363 — intervention group
Group type: COMPARATOR
Intervention: Randomized control group
Number of subjects: 0
Study 29795295 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% GRFT gel (HEC formulation)
Number of subjects: 6
Study 29795295 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (HEC formulation)
Number of subjects: 6
Study 27180881 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnebia euchroma ointment (AEO)
Number of subjects: 45
Study 27180881 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream (SSD)
Number of subjects: 45
Study 25148614 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy
Number of subjects: 28
Study 25148614 — intervention group
Group type: COMPARATOR
Intervention: Mandibular osteotomy (surgical control group)
Number of subjects: 28
Study 25148614 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical controls
Number of subjects: 28
Study 22447888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 452
Study 22447888 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual aspiration thrombectomy
Number of subjects: 452
Study 21455255 — intervention group
Group type: EXPERIMENTAL
Intervention: DOCp53 group (trans-tracheal Adp53 injection at 1 × 10(12) vp on day 1 and day 8, plus docetaxel at 75 mg/m² on day 2)
Number of subjects: 40
Study 21455255 — intervention group
Group type: COMPARATOR
Intervention: DOC group (docetaxel at 75 mg/m² on day 1)
Number of subjects: 40
Study 18639268 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine jelly instilled proximal to the stone before and after fragmentation
Number of subjects: 50
Study 18639268 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lidocaine jelly)
Number of subjects: 50
Study 16557619 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants sentenced 16‐ and 17‐year‐old defendants similarly to 18‐ and 25‐year‐old defendants.
Number of subjects: 235
Study 16557619 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived level of the defendant's responsibility.
Number of subjects: 235
Study 16557619 — intervention group
Group type: EXPERIMENTAL
Intervention: General opinion about capital sentences.
Number of subjects: 235
Study 16557619 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' comfort level with sentencing.
Number of subjects: 235
Study 24944393 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg plus delapril 30 mg once daily for 12 weeks (Group 1)
Number of subjects: 312
Study 24944393 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 10 mg plus delapril 30 mg once daily for 12 weeks (Group 2)
Number of subjects: 312
Study 10903019 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (600 U/kg s.c. on day 14 and if needed on day 7 before surgery)
Number of subjects: 60
Study 10903019 — intervention group
Group type: EXPERIMENTAL
Intervention: ANHD (implemented after induction of anaesthesia)
Number of subjects: 60
Study 10903019 — intervention group
Group type: COMPARATOR
Intervention: PDAB (conventional PDAB up to 3 U starting 4 weeks before surgery)
Number of subjects: 60
Study 10903019 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO with moderate ANHD
Number of subjects: 60
Study 8855179 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin and a combination of amoxicillin and clavulanic acid for 3 days after hemorrhage (group 3)
Number of subjects: 119
Study 8855179 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 119
Study 1900488 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen/progestin administration
Number of subjects: 0
Study 1900488 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropins
Number of subjects: 0
Study 6621660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan in 10 per cent glucose
Number of subjects: 20
Study 6621660 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine in 5 per cent glucose
Number of subjects: 20
Study 6621660 — intervention group
Group type: COMPARATOR
Intervention: Routine formula (Similac)
Number of subjects: 20
Study 31987245 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric treatment
Number of subjects: 101
Study 31987245 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 101
Study 30882238 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study 28913611 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobutrol (GB)
Number of subjects: 54
Study 28913611 — intervention group
Group type: COMPARATOR
Intervention: Gadoterate (GT)
Number of subjects: 54
Study 25307886 — intervention group
Group type: COMPARATOR
Intervention: Optilene LP mesh (OLP group)
Number of subjects: 145
Study 25307886 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping Parietex ProGrip mesh (PPG group)
Number of subjects: 145
Study 23881433 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall training (12 training sessions, 60 min each, over 6 weeks)
Number of subjects: 18
Study 23881433 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 22166108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec Plus (C+)
Number of subjects: 120
Study 22166108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervitec (C)
Number of subjects: 120
Study 22166108 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 120
Study 19307437 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression, sclerotherapy, surgery, and endoluminal treatments
Number of subjects: 0
Study 17584568 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI (group A, n = 36)
Number of subjects: 96
Study 17584568 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase followed by PCI within 24 hours (group B, n = 30)
Number of subjects: 96
Study 17584568 — intervention group
Group type: COMPARATOR
Intervention: Tenecteplase alone (group C, n = 30)
Number of subjects: 96
Study 15493034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser irradiation (685 nm, 10 minutes, 30 mW)
Number of subjects: 70
Study 15493034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser irradiation (830 nm, 5 minutes, 60 mW)
Number of subjects: 70
Study 15493034 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimycotic self-treatment with antifungal oral gel and antiseptic solution for dentures
Number of subjects: 70
Study 15493034 — intervention group
Group type: COMPARATOR
Intervention: Placebo-sham irradiation
Number of subjects: 70
Study 11518097 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to remove finger when feeling heat
Number of subjects: 10
Study 11518097 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to remove finger when feeling unpleasant
Number of subjects: 10
Study 11518097 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to remove finger when feeling pain
Number of subjects: 10
Study 11518097 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions to remove finger when could no longer tolerate pain
Number of subjects: 10
Study 11518097 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher stimulus intensities
Number of subjects: 10
Study 9752814 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited surgery (planned to take place within 6 weeks)
Number of subjects: 208
Study 9752814 — intervention group
Group type: COMPARATOR
Intervention: Routine surgery (routine waiting time, 7-12 months)
Number of subjects: 208
Study 9752814 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited surgery
Number of subjects: 208
Study 8141577 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet induction treatment
Number of subjects: 65
Study 3125973 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg thymostimulin (TS) i.m. daily for 35 days (G1)
Number of subjects: 19
Study 3125973 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg thymostimulin (TS) i.m. every other day for 35 days (G2)
Number of subjects: 19
Study 3125973 — intervention group
Group type: COMPARATOR
Intervention: No treatment (G3)
Number of subjects: 19
Study 3125973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin maintenance therapy
Number of subjects: 19
Study 3125973 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro assessment of IL-2 and IFN-gamma synthesis in TS-treated patients
Number of subjects: 19
Study 3125973 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin treatment
Number of subjects: 19
Study 30597771 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04447943 25 mg
Number of subjects: 30
Study 30597771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28202779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting-mimicking diet (FMD) for 5 consecutive days per month for 3 months
Number of subjects: 100
Study 28202779 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted diet for 3 months
Number of subjects: 100
Study 28202779 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc analysis of both FMD arms
Number of subjects: 100
Study 26548737 — intervention group
Group type: COMPARATOR
Intervention: Typical chiropractic care only (manual therapy and exercises)
Number of subjects: 34
Study 26548737 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical chiropractic care with daily home use of the self-acupressure pillow (SAP)
Number of subjects: 34
Study 23036940 — intervention group
Group type: EXPERIMENTAL
Intervention: Total activity minutes/week (AM)
Number of subjects: 301
Study 23036940 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking minutes/week (WM)
Number of subjects: 301
Study 21625929 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin
Number of subjects: 927
Study 21625929 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 927
Study 21625929 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin and Tamoxifen (combined)
Number of subjects: 927
Study 18452778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy (switched from UFH/ENOX)
Number of subjects: 4215
Study 18452778 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy (naive to antithrombin therapy)
Number of subjects: 4215
Study 18452778 — intervention group
Group type: COMPARATOR
Intervention: UFH/ENOX plus GP IIb/IIIa inhibitor (consistent therapy)
Number of subjects: 4215
Study 18452778 — intervention group
Group type: COMPARATOR
Intervention: UFH/ENOX plus GP IIb/IIIa inhibitor (naive patients)
Number of subjects: 4215
Study 17022864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin
Number of subjects: 2959
Study 17022864 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 2959
Study 12748969 — intervention group
Group type: EXPERIMENTAL
Intervention: Organized mammography screening
Number of subjects: 1942
Study 12748969 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceived susceptibility (PS)
Number of subjects: 1942
Study 12748969 — intervention group
Group type: EXPERIMENTAL
Intervention: False positive screening finding
Number of subjects: 1942
Study 12748969 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE)
Number of subjects: 1942
Study 11074742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler plus nicotine patch (delivering 15 mg of nicotine per 16 hours) for 6 weeks, then inhaler plus placebo patch for 6 weeks, then inhaler alone for 14 weeks
Number of subjects: 400
Study 11074742 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhaler plus placebo patch for 12 weeks, then inhaler for 14 weeks
Number of subjects: 400
Study 9051945 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert Toothbrush
Number of subjects: 0
Study 1395118 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 0
Study 2866966 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenolol
Number of subjects: 6
Study 2866966 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 2866966 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6
Study 2866966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2866966 — intervention group
Group type: COMPARATOR
Intervention: Propranolol and Atenolol (Control Beta-blockers)
Number of subjects: 6
Study 30657353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 2226
Study 30657353 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 2226
Study 30657353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction-based treatment
Number of subjects: 2226
Study 30657353 — intervention group
Group type: COMPARATOR
Intervention: Monochemotherapy
Number of subjects: 2226
Study 28482405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon α‐2b (Y shape, 40 kD) injection (180 µg/week) combined with ribavirin
Number of subjects: 561
Study 28482405 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose Peg‐IFN‐α‐2a combined with ribavirin
Number of subjects: 561
Study 25846329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis users (n=46)
Number of subjects: 116
Study 25846329 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 116